Mindful Innovation

Mastering Challenges. Compassion for Patients. Transforming Medicine.

At Marinus Pharmaceuticals, our passionate team of experts is constantly innovating with the aim to drastically improve lives affected by rare epilepsies and CNS disorders.

Purple Ring


Improving lives of patients suffering from seizures and CNS disorders 

Learn more

Blue Ring


Maximizing the reach of ganaxolone to make a difference in patient lives  

Learn more

Green Ring


We partner with leading epilepsy and CNS patient advocacy groups 

Learn more

Expanded Access Program

Marinus launched the Expanded Access Program (EAP) for CDKL5 in January 2020.
This program allows qualified patients to receive the investigational drug ganaxolone for CDD.

We are laser focused on treating patients with severe, rare forms of epilepsy, implementing a clinical trial strategy that is guided by our strong scientific rationale, and unlocking the potential of ganaxolone across a range of CNS disorders. 

— Scott Braunstein, M.D., CEO, Marinus Pharmaceuticals

  • Ganaxolone

    Dedicated to the development of ganaxolone

    We are dedicated to maximizing the value of ganaxolone as we investigate its potential in a number of diversified indications.

    Learn more about ganaxolone

  • Pipeline

    Discover the science behind ganaxolone

    Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings.

    View our pipeline

  • Focus Areas

    Focused on rare seizure and CNS disorders

    We are developing breakthrough therapies in status epilepticus, tuberous sclerosis complex, and CDKL5 deficiency disorder.

    Learn more about our focus areas

  • Trials

    Our goal is developing safe and effective treatments

    We are conducting high quality research in-house, with our scientific advisory board and external consultants to ensure patients are receiving innovative and safe treatment options.

    Learn more about our active trials on ClinicalTrials.gov

Providing a range of clinical trials to develop innovative treatments for patients

Physician Child Epilepsy 1

Status Epilepticus

Striving to maintain seizure control

Developing therapies with the potential to provide rapid cessation of status epilepticus and prevent escalation of treatment

Learn more

Rare Orphan Epilepsies

Aspiring to give children significantly less seizures and better quality of life

Ganaxolone offers the potential to safely decrease seizure frequency in children with refractory epilepsy

Learn more

Advocacy & Related Activities

Fostering a community for those impacted by rare diseases

Collaborating with key groups to support patients and their families, working to lessen the burden of rare diseases and disorders

Learn more

Svg Graphic Neurology 1

Follow Us on Twitter

#CDKL5 stands for cyclin-dependent kinase-like 5 and is located on the X chromosome. Due to the gene’s location, CDD mainly affects girls. #CDKL5AwarenessMonth #CDKL5Forward

Our Expanded Access Program for #CDD allows qualified US patients to receive the investigational drug ganaxolone.

Physicians and caregivers can learn more about how to request participation by visiting: https://marinuspharma.com/science-pipeline/expanded-access-program/

Here is the Agenda for the CDKL5 Alliance Conference on the 19th June https://www.cdkl5alliance.org/cdkl5-alliance-international-virtual-family-conference-agenda/

Home Join The Marinus Team

Want to make an impact?

We are always looking for dedicated and passionate professionals who want to make a positive difference in the lives of those affected by rare epilepsies and CNS disorders.

Join us